214 related articles for article (PubMed ID: 19348416)
21. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy.
Kempf DJ; Sham HL; Marsh KC; Flentge CA; Betebenner D; Green BE; McDonald E; Vasavanonda S; Saldivar A; Wideburg NE; Kati WM; Ruiz L; Zhao C; Fino L; Patterson J; Molla A; Plattner JJ; Norbeck DW
J Med Chem; 1998 Feb; 41(4):602-17. PubMed ID: 9484509
[TBL] [Abstract][Full Text] [Related]
22. In situ formation of nanoparticles upon dispersion of melt extrudate formulations in aqueous medium assessed by asymmetrical flow field-flow fractionation.
Kanzer J; Hupfeld S; Vasskog T; Tho I; Hölig P; Mägerlein M; Fricker G; Brandl M
J Pharm Biomed Anal; 2010 Nov; 53(3):359-65. PubMed ID: 20447794
[TBL] [Abstract][Full Text] [Related]
23. Ritonavir alert.
Proj Inf Perspect; 1998 Sep; (25):12. PubMed ID: 11365839
[TBL] [Abstract][Full Text] [Related]
24. FDA notifications. Generic lopinavir/ritonavir approved by FDA.
AIDS Alert; 2009 May; 24(5):59. PubMed ID: 19452652
[No Abstract] [Full Text] [Related]
25. Nanoparticle-in-microparticle oral drug delivery system of a clinically relevant darunavir/ritonavir antiretroviral combination.
Augustine R; Ashkenazi DL; Arzi RS; Zlobin V; Shofti R; Sosnik A
Acta Biomater; 2018 Jul; 74():344-359. PubMed ID: 29723705
[TBL] [Abstract][Full Text] [Related]
26. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
Bénard A; Damond F; Campa P; Peytavin G; Descamps D; Lascoux-Combes C; Taieb A; Simon F; Autran B; Brun-Vézinet F; Chêne G; Matheron S;
AIDS; 2009 Jun; 23(9):1171-3. PubMed ID: 19349850
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Boulanger C; Hollender E; Farrell K; Stambaugh JJ; Maasen D; Ashkin D; Symes S; Espinoza LA; Rivero RO; Graham JJ; Peloquin CA
Clin Infect Dis; 2009 Nov; 49(9):1305-11. PubMed ID: 19807276
[TBL] [Abstract][Full Text] [Related]
28. Stereoselective hydroazidation of amino enones: synthesis of the ritonavir/lopinavir core.
Adamo I; Benedetti F; Berti F; Campaner P
Org Lett; 2006 Jan; 8(1):51-4. PubMed ID: 16381565
[TBL] [Abstract][Full Text] [Related]
29. Water-soluble prodrugs of an Aurora kinase inhibitor.
Oslob JD; Heumann SA; Yu CH; Allen DA; Baskaran S; Bui M; Delarosa E; Fung AD; Hashash A; Hau J; Ivy S; Jacobs JW; Lew W; Maung J; McDowell RS; Ritchie S; Romanowski MJ; Silverman JA; Yang W; Zhong M; Fuchs-Knotts T
Bioorg Med Chem Lett; 2009 Mar; 19(5):1409-12. PubMed ID: 19186057
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and in vitro biological evaluation of valine-containing prodrugs derived from clinically used HIV-protease inhibitors.
Roche D; Greiner J; Aubertin AM; Vierling P
Eur J Med Chem; 2008 Jul; 43(7):1506-18. PubMed ID: 17950955
[TBL] [Abstract][Full Text] [Related]
31. Aminocarbonyloxymethyl ester prodrugs of flufenamic acid and diclofenac: suppressing the rearrangement pathway in aqueous media.
Ribeiro L; Silva N; Iley J; Rautio J; Järvinen T; Mota-Filipe H; Moreira R; Mendes E
Arch Pharm (Weinheim); 2007 Jan; 340(1):32-40. PubMed ID: 17206608
[TBL] [Abstract][Full Text] [Related]
32. Enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions.
Dhore PW; Dave VS; Saoji SD; Bobde YS; Mack C; Raut NA
Pharm Dev Technol; 2017 Feb; 22(1):90-102. PubMed ID: 27291246
[TBL] [Abstract][Full Text] [Related]
33. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.
Lin JH; Chen IW; Vastag KJ; Ostovic D
Drug Metab Dispos; 1995 Jul; 23(7):730-5. PubMed ID: 7587962
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects.
McRae M; Clay PG; Anderson PL; Glaros AG
Pharmacotherapy; 2009 Aug; 29(8):937-42. PubMed ID: 19637947
[TBL] [Abstract][Full Text] [Related]
35. Directed reductive amination of beta-hydroxy-ketones: convergent assembly of the ritonavir/lopinavir core.
Menche D; Arikan F; Li J; Rudolph S
Org Lett; 2007 Jan; 9(2):267-70. PubMed ID: 17217281
[TBL] [Abstract][Full Text] [Related]
36. Optimized administration regimen of lopinavir for a myocardial ischaemia reperfusion study in Sprague-Dawley rats.
Katayama M; Jiamsripong P; Bukatina AE; Lombari TR; McMahon EM; Gades NM; Belohlavek M
Lab Anim; 2013 Apr; 47(2):122-6. PubMed ID: 23563365
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and in vitro biological evaluation of mannose-containing prodrugs derived from clinically used HIV-protease inhibitors with improved transepithelial transport.
Roche D; Greiner J; Aubertin AM; Vierling P
Bioconjug Chem; 2006; 17(6):1568-81. PubMed ID: 17105238
[TBL] [Abstract][Full Text] [Related]
38. New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration.
Hamada Y; Ohtake J; Sohma Y; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem; 2002 Dec; 10(12):4155-67. PubMed ID: 12413869
[TBL] [Abstract][Full Text] [Related]
39. Designing for topical delivery: prodrugs can make the difference.
Sloan KB; Wasdo S
Med Res Rev; 2003 Nov; 23(6):763-93. PubMed ID: 12939791
[TBL] [Abstract][Full Text] [Related]
40. Lack of evidence for an effect of lopinavir/ritonavir on tenofovir renal clearance.
Ray AS; Wright MR; Rhodes GR
Clin Pharmacol Ther; 2008 Dec; 84(6):660; author reply 661. PubMed ID: 18615003
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
